Editorial
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
Abstract
Immune Check Point inhibitors (ICIs) have demonstrated efficacy in advanced stage solid tumors including non-small cell lung cancer (NSCLC), CTLA4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors being the most studied drugs.
